( 1 ) Analyses failed to provide evidence of a relationship between maternal buprenorphine dose at delivery and any of the 10 outcomes ( all p-values > .48 ) and ( 2 ) significant mean differences between the untreated ( n = 31 ) and treated ( n = 27 ) for NAS groups were found for duration of neonatal hospital stay and NAS peak score ( both p-values < .001 ) .